Value and difficulties of a common European strategy for recurrent Wilms' tumor

Expert Review of Anticancer Therapy

Volumn 9, Issue 6, 2009, Pages 693-696

  Spreafico, Filippo ^a   Pritchard Jones, Kathy ^b   Bergeron, Christophe ^c   de Kraker, Jan ^d   Dallorso, Sandro ^e   Graf, Norbert ^f  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CENTRE LÉON BÉRARD   (France)

^d EMMA CHILDREN S HOSPITAL   (Netherlands)

^e G GASLINI INSTITUTE   (Italy)

^f SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; EDITORIAL; EVENT FREE SURVIVAL; HUMAN; NEPHRECTOMY; NEPHROBLASTOMA; OVERALL SURVIVAL; PRACTICE GUIDELINE; STEM CELL TRANSPLANTATION; CHILD; CLINICAL TRIAL; EUROPE; INTERNATIONAL COOPERATION; METHODOLOGY; MORTALITY; PATHOPHYSIOLOGY; RISK FACTOR; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

CHILD; CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; INTERNATIONAL COOPERATION; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; WILMS TUMOR;

EID: 68849103069     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.45     Document Type: Editorial

References (23)

1. Green DM, Breslow NE, Beckwith JB et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J. Clin. Oncol. 16, 237-245 (1998).
2. de Kraker J, Graf N, van Tinteren H et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 364, 1229-1235 (2004).
3. Tournade MF, Com-Nougué C, de Kraker J et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J. Clin. Oncol. 19, 488-500 (2001).
4. Tournade MF, Lemerle J, Brunat-Mentigny M et al. Ifosfamide is an active drug in Wilms' tumor: a Phase II study conducted by the French Society of Pediatric Oncology. J. Clin. Oncol. 6, 793-796 (1988).
5. Pein F, Pinkerton R, Tournade MF et al. Etoposide in relapsed Wilms' tumor: a Phase II study by the French Society of Pediatric Oncology. J. Clin. Oncol. 11, 1478-1481 (1993).
6. De Camargo B, Melarango R, Saba e Silva N et al. Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group. Med. Ped. Oncol. 22, 258-260 (1994).
7. Pein F, Tournade MF, Zucker JM et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor - a Phase II study by the French Society of Pediatric Oncology. J. Clin. Oncol. 12, 931-936 (1994).
8. Metzger ML, Stewart CF, Freeman III BB et al. Topotecan is active against Wilms' tumor: results of a multi-institutional Phase II study. J. Clin. Oncol. 21, 3130-3136 (2007).
9. Pein F, Michon J, Valteau-Couanet D et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J. Clin. Oncol. 16, 3295-3301 (1998).
10. Kremens B, Gruhn B, Klingebiel T et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant. 30, 893-898 (2002).
11. Campbell AD, Cohn SL, Reynolds M et al. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J. Clin. Oncol. 22, 2885-2890 (2004).
12. Abu-Ghosh AM, Krailo MD, Goldman SC et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann. Oncol. 13, 460-469 (2002).
13. Malogolowkin M, Cotton CA, Green DM et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr. Blood Cancer 50, 236-241 (2008).
14. Spreafico F, Bisogno G, Collini P et al. Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem-cell support: experience by the Italian Association of Pedaitric Hematology and Oncology. Pediatr. Blood Cancer 51, 23-28 (2008).
15. Hale J, Hobson R, Moroz V, Sartori P. Results of UK Children's Cancer and Leukemia Group (CCLG) protocol for relapsed Wilms tumor (UKWR): unified relapse strategy improves outcome. Presented at: 40th Meeting of International Society of Paediatric Oncology. Berlin, Germany, 2-6 October 2008.
16. Green DM, Cotton CA, Malogolowkin M et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr. Blood Cancer 48, 493-499 (2007).
17. Garaventa A, Hartmann O, Bernard JL et al. Autologous bone marrow transplantation for pediatric Wilms' tumour: the experience of the European Bone Marrow Transplantation Solid Tumour Registry. Med. Pediatr. Oncol. 22, 11-14 (1994).
18. Zils K, Furtwangler R, Reinhard H, Alkassar M, Graf N. Consultation within the nephroblastoma trial SIOP 2001/GPOH as part of the workload in the trial office. Klin. Paediatr. 3, 183-188 (2008).
19. Bardeesy N, Beckwith JB, Pelletier J. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res. 55, 215-219 (1995).
20. Natrajan R, Little SE, Sodha N et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J. Pathol. 211, 52-59 (2007).
21. Williams RD, Hing SN, Greer BT et al. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer 41(1), 65-79 (2004).
22. Huang CC, Gadd S, Breslow N et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group. Clin. Cancer Res. 15, 1770-1778 (2009).
23. Grundy PE, Breslow NE, Li S et al. Loss of heterozygosity for chromosome 1p and 16q is an adverse prognostic factor in favourable histology Wilms tumor: a report from the National Wilms Tumor Study Group. J. Clin. Oncol. 23, 7312-7321 (2005).